precisionmedicineonline20h
Restore Vision Doses First Retinitis Pigmentosa Patient in Phase I/II Gene Therapy Trial
The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.
Science Daily14d
New potential treatment for inherited blinding disease retinitis pigmentosa
Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...
Healio8d
VIDEO: MCO-010 demonstrates vision improvements, safety in retinitis pigmentosa
In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.
Nikkei Asia1d
Japan researchers target degenerative eye disease with gene therapy
TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...
DVLA eye conditions warning as drivers could face £1,000 fine
Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition ...